

(51) International Patent Classification:
C07K 16/00 (2006.01)(21) International Application Number:
PCT/US2020/012057(22) International Filing Date:
02 January 2020 (02.01.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/787,867 03 January 2019 (03.01.2019) US

(71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: STEVENS, Jennitte LeAnn; c/o Amgen Inc., One Amgen Center Drive, Legal Dept-Patent Operations, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). TEMEL, Deniz; c/o Amgen Inc., One Amgen Center Drive, Legal Dept-Patent Operations, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). ESTES, Bram; c/o Amgen Inc., One Amgen Center Drive, Legal Dept-Patent Operations, M/S 28-5-A, Thousand Oaks, Califor-

nia 91320-1799 (US). AGRAWAL, Neeraj Jagdish; c/o Amgen Inc., One Amgen Center Drive, Legal Dept-Patent Operations, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ENGINEERING MONOCLONAL ANTIBODIES TO IMPROVE STABILITY AND PRODUCTION TITER

FIG. 1A

Avg(titer) vs. MTX, DNA construct

(57) Abstract: Presented herein are methods directed to engineering monoclonal antibodies and antibody variants to improve stability and their production in culture. Specifically, the monoclonal antibodies can be engineered at heavy chain residue 56 (A_{Ho} numbering) to a glycine, alanine, or serine, and/or engineered at position 80 (A_{Ho}) to be a hydrophobic residue such as alanine, isoleucine, phenylalanine, leucine, methionine, or valine.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

03 September 2020 (03.09.2020)